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Abstract 
Giardiasis is a common intestinal protozal parasitic infection of the pet dog and cat 
population.  Veterinarians often have difficulty correctly diagnosing this parasite.  Studies were 
conducted to compare the zinc sulfate double centrifuge fecal flotation to the SNAP (registered 
trademark) Giardia fecal ELISA test manufactured by IDEXX laboratories Inc. in purpose bred 
beagles and shelter and commercial kennel dogs.  In these evaluations the zinc sulfate double 
centrifuge fecal flotation and fecal ELISA test performed similarly. Both tests performed better 
in the shelter and commercial kennel dog population than the chronically infected purpose bred 
beagles.  There was an increase in number of positive animals identified when 3 consecutive 
daily samples were evaluated as compared to any one individual day for either test method.  Post 
treatment evaluation of the diagnostic tests was performed in 23 laboratory beagles.  Each beagle 
was treated for 3 consecutive days with Drontal plus and then bathed on the last day of treatment 
and fecal samples were collected from the treated dogs every other day starting one day post 
treatment for 21 days.  It was found that all beagles were negative on zinc sulfate double 
centrifugation fecal flotation, fecal ELISA and IFA within 24 hours of treatment and nineteen 
(82.6%) of the beagles did not re-shed cysts during the 21 day post-treatment evaluation period. 
Four beagles returned to shedding cysts (Flotation or IFA positive) between days 17 and 21. 
These findings suggest that a positive test within a week of treatment is likely the result of 
inappropriate treatment. After the prepatent period, positive results may occur due to a return to 
shedding, reinfection or inappropriate treatment.  Chronically infected laboratory beagles may 
not be a good model for acute Giardia infections as these dogs are rarely clinically ill and 
detection is more difficult.  
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CHAPTER 1 - Literature Review of Giardia spp. 
HISTORY 
 
Antony van Leeuwenhoek first described Giardia in his own stool in 1681.1  He was a 
fabric merchant who made many of the first microscopes.  He viewed and described many 
specimens such as bacteria, dog sperm and Giardia.  In 1859, a Czech physician named Vilem 
Lambl observed Giardia in the stools of children with diarrhea, which he called Cermomonas 
intestinalis.  He described and drew the trophozoites and cyst forms.  He believed them to be 
commensal organisms, not pathogens.  Raphael Anatole Émile Blanchard renamed the organism 
Lamblia intestinalis in 1888.2  Charles Wardell Stiles changed the name to Giardia lamblia in 
1915.3   He suspected Giardia to be a pathogen when he found a correlation between soldiers 
with diarrhea and the organism.  Not until 1954 did the American physician Robert Rendtorff, 
produced detailed studies linking the parasite with the disease.4  The World Health Organization 
added Giardia to the list of parasitic diseases in 1981.2  
 
TAXONOMY 
 
 Kingdom – Protista 
 Subkingdom – Protozoa 
 Phylum – Sacromastigophora 
 Subphylum – Mastigophora 
 Class – Zoomastigophora 
 Order – Diplomonadida 
 Family – Hexamitidae 
 Genus – Giardia 
 
Over 50 species of Giardia have been described.  Previously, the various Giardia spp. 
were given species names and classified by the host from which the organism was isolated and 
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the phenotypic description.5  Recently, the list of species has been condensed based on molecular 
characteristics.  The list now includes:5-7  
 
Table 1.1  Giardia species and hosts  
Species Hosts 
G. agilis                                     Amphibians 
G. ardeae                                   Birds 
G. microti  Muskrats and Voles 
G. muris                                     Mice   
G. psittaci                                  Birds 
G. intestinalis 
           
Wide range of domestic and wild 
animals including humans, dogs, & cats 
 
 
 
   
Synonyms for Giardia intestinalis are G. duodenalis and G. lamblia.  There is 
considerable diversity within G. intestinalis. Groupings called assemblages with further 
subgroups have been identified. The assemblages are based on PCR techniques using conserved 
genetic loci including glutamate dehydrogenase (GDH), elongation factor 1-α (ef1-α), Triose 
phosphate isomerase (TPI), and rDNA.5, 7  These assemblages are as follows:5, 7, 8 
 
Table 1.2 Assemblages of Giardia intestinalis and hosts 5,7,8 
Assemblages Hosts 
Assemblage  A     
          Subgroup I, II                       
Humans, primates, dogs, 
     cats, cattle, rodents, wild 
     mammals  
Assemblage  B      
                              
Humans, primates, dogs, 
     horses, cattle 
Assemblage  C                           Dogs 
Assemblage  D                           Dogs 
Assemblage  E                                                  Cattle, sheep, pigs 
 Cats 
Assemblage  G Domestic rats 
Muskrats /Voles                         Muskrats /Voles                         
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Recently another taxonomy classification scheme has been suggested. This supports the 
idea that species specific assemblages may be different Giardia species. The proposed 
renaming is as follows.9  
 
Table 1.3 Proposed Giardia species, previous assemblage and hosts 
Proposed Giardia  species Previous assemblage Host 
G. agilis  Amphibians 
G. ardeae                                     Birds 
G. muris                                       Rodents 
G. psittaci          Birds 
G. duodenalis Assemblage A   Humans and other  
primates, dogs, cats, 
livestock                         
G. enterica Assemblage B   Humans, primates,  dogs  
G. canis Assemblage C   Dogs 
G. cati Assemblage F   Cats 
G. bovis Assemblage E   Cattle and other hoofed 
livestock  
G. simondi Assemblage G   Rats 
These suggested taxonomy changes have not been adopted.  
 
MORPHOLOGY 
 
Giardia intestinalis is a biphasic parasite. Trophozoites are the intestinal motile form; 
cysts are the environmentally more resistant form.  Trophozoites are 12 - 15μm long by 5 - 9 μm 
wide. They are tear-drop shaped which are dorsally ventrally flattened.  There are two anteriorly 
positioned nuclei.10  The ventral surface is concave with a ventral adhesive disc.  There are four 
pairs of flagella (anterior, posterior, caudal and ventral) which in conjunction with the ventral 
disc aid in adherence to the host intestinal epithelium.  The median bodies are found posterior to 
the ventral disc and their function is not known. These characteristics give the trophozoites the 
appearance of a face.1, 10, 11 
The cysts are 8 - 12μm long and 5 - 8 μm wide with four nuclei and intracytoplasmic 
axonemes visible. Cysts contain a mitotically arrested trophozoite.10  The cyst wall 0.3 to 0.5 μm 
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thick and composed of two layers.  This tough outer covering allows the organism to be 
environmentally resistant.10 
LIFE CYCLE 
 
 Giardia has two life stages; environmentally resistant cysts and the intestinal dwelling 
replicating trophozoites.  The host usually acquires the organism by orally ingesting cysts.  Ten 
to 100 cysts are required to establish an infection in the human host.2  As cysts travel through the 
stomach, the decrease in pH is a stimulus to the parasite to prepare for excystation.  Upon 
entering the duodenum, the environment changes to a more alkaline pH with the presence of 
pancreatic enzymes trypsin and chymotrypsin.  These changes signal for excystation to occur.  
The presence of a cysteine protease in the parasite’s endosome-lyosome like vacuoles aids in 
triggering the excystation process.11  It has been suggested that the mechanical activity of the 
flagella may have an important part in triggering the opening of the cyst wall during the 
excystation process.12  Separation of the cyst wall allows the organism emerge and divide 
quickly. The trophozoites numbers increase rapidly by binary fission.  
Attachment of the parasite to the host epithelium is a complex process.  In vitro it has 
been shown that it is necessary for both intestinal epithelial cells and the trophozoites to be 
metabolically active for attachment to take place.  Fimbrial extensions of the extracellular matrix 
of epithelial cells come in contact with the trophozoites. Surface lectins may aid in binding the 
trophozoite to the epithelial cell. The lateral crest and the ventrolateral flange of the parasite were 
observed to make direct contact and imprints in the cultured epithelial cells.13  The force that 
maintains the attachment is the negative pressure generated beneath the ventral disk. This force 
is made by a combination of mechanical and hydrodynamic forces generated by the ventral 
flagella and contractile proteins of the ventral disk.13  Ventral disk tubulin appears to be different 
from that of the flagella’s tubulin.  The organism can adhere when flagellar function is abnormal, 
but if ventral disk tubulin is experimentally alters the organism cannot adhere to the intestinal 
surface.11  Also, trophozoites have variant surface proteins covering their surface. Giardia has 
approximately 190 variant surface proteins genes in its genome. Only one surface protein is 
expressed at a time and the surface protein is changed every 6 -13 generations.  This antigenic 
variation may explain how the organism escapes the host’s protective mechanisms to establish 
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repetitive and persistent infections.1,5  Two hypotheses have been suggested to explain variant 
surface proteins.  First, changing the surface antigens enables the parasite to evade the infected 
host’s immune system. The host will mount a humoral response to the first surface antigen only 
later to be faced with a new surface antigen.  The second hypotheses states that variable surface 
proteins are needed to survive in different intestinal environments.2,11 
Non-adhered trophozoites travel down the gastrointestinal tract with the ingesta and it is 
in the lower jejunum that the complex process of encystation begins.  The presence of bile salts 
and a decrease in cholesterol signal the trophozoites to initiate the encystation process.12  The 
trophozoites’ endoplasmic reticulum produces the building blocks which form the outer cyst 
wall.  The material is packaged into encystation vesicles.  The vesicles transport the material to 
the cell surface where it is released.  After the cell wall components are released the vesicle can 
reseal and may be endocytosed by the parasite or remain empty.12  The completed cyst wall 
consists of a thick fibrillar outer cover and two inner cell membranes adjacent to the plasma 
membrane of the parasite.  D-galactosamine polymer, cyst wall protein 1, cyst wall protein 2, 
and cyst wall protein 3 have been identified as structural components of the cyst wall.2  The 
membrane components are deposited first at the lateral flange area. This causes cell rounding and 
a depression in the central ventral region of the parasite. Flagella are modified and are 
internalized by the elongating ventral membrane. The caudal flagella remain external until the 
last steps of encystation, and then they are retracted into a vacuole within the cysts. These 
flagella can be observed to be beating within the cyst.14  This cyst wall is what makes the cysts 
environmentally resistant.2    
As cyst wall production is occurring, the trophozoite partially divides. Trophozoites 
undergo nuclear replication but not cytokinesis. These nuclei are genetically separate from each 
other.  Daughter cells inherit one copy of each nucleus.11, 15  The nuclei can be asymmetrical in 
their karyotypes and DNA content.  It has been proposed that there is at least one copy of each 
chromosome in each nucleus.  To what extent they are different has yet to be discovered.11  
When the encystation process is completed, the cyst contains four nuclei, two bi-lobed adhesive 
disks and doubled flagella which are encapsulated by the cyst wall.1  Further division of the 
mitotically arrested trophozoite will occur during excystation.  The newly formed cysts are 
passed into the environment with the feces.  Ingestion of cysts by a new host starts the life cycle 
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over again. The prepatent period, the time from ingestion of cysts to shedding cysts in the feces 
has been shown to be 5 – 16 days. 16,18,19 
CYST RESISTANCE 
 
Cysts have been shown to be viable for 56 to 84 days when suspended in lake water in 
winter conditions.20  Survival of cysts in the environment shows a distinct temperature 
dependence.21  When cysts that were suspended in clean tap water at a pH of 7.6 and were held 
at 4oC in the laboratory they remained viable for 18 weeks.  At 24oC cysts survived up to 14 
weeks.  Cysts maintained at 37oC were killed in 3 weeks.  While at 50oC cysts were considered 
nonviable within 12 hours.  When the temperature was decreased to -20oC, all cysts were killed 
in 24 hours.  Cysts in feces stored at 24oC were no longer viable after 4 weeks.  Air drying was 
also detrimental to cysts, 90% were killed within 24 hours.21  An experiment exposing cysts to 
Sterinol, a quaternary ammonium detergent, showed that at 0.5% concentration of the 
disinfectant, cidal effects were seen within 10 – 30 minutes.  At 0.1% concentration 84% of the 
cysts were still viable after 30 minutes. The determination of viability was based on the eosin-
exclusion method where cysts are exposed to a 1% eosin aqueous solution for 10 minutes.  Cysts 
that became stained were considered nonviable.21  
Resistance of cysts to supermarket disinfectants has also been evaluated.22  The products 
evaluated were Ajax and Old Dutch (chlorinated powders), Javex (liquid chlorine), Soft Scrub 
with bleach (semisolid chlorinated product), Lysol spray, Dettol, Pine Glo and Pine Sol ( liquid 
phenols), ammonia and vinegar.  The liquid phenols, ammonia and vinegar were diluted to half 
strength and the chlorinated products were serially diluted.  Inactivation of cysts was achieved 
with 1 minute exposure to half strength Pine Glo and Dettol, full strength Lysol spray, and 
chlorinated products (powders, liquids, and semisolids) were diluted to 100 - 166 ppm of free 
active chlorine (FAC).  Ammonia, vinegar and Pine Sol had a reduced ability to decrease cyst 
viability compared to the other disinfectants.  Cyst viability was determined by the eosin-
exclusion method, excystation and the ability of cysts to cause a patent infection in mice.  The 
authors of the above study stated effective disinfection could be obtained by surface cleaning and 
then exposed for one minute to half strength Pine Glo, half strength Dettol, full strength Lysol 
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spray, Soft Scrub with bleach diluted 1/10 (150 ppm of FAC), Ajax diluted to 1/30 (166 ppm of 
FAC), or Javex with a dilution of 1/5 (100 ppm of FAC).22    
PATHOLOGY 
 
The degree of symptoms suffered by the patient depends on the virulence of the 
organism, and on host factors including age, nutritional status, immune status and concurrent 
disease.  The adhesion of the trophozoites can cause apoptotis of the intestinal epithelium 
increasing the permeability of the barrier. Tight junctions of the epithelium are disrupted adding 
to the increase in permeability. This increase in intestinal permeability in turn causes an 
inflammatory response and villous blunting.8  The chain of events that occur during infection 
with Giardia may lead to a combination of malabsorption and hypersecretion of electrolytes 
resulting in diarrhea.  Although diarrhea is the most common clinical sign other signs include 
weight loss, flatulence, and lethargy. A large variability in severity of clinical signs can be 
observed.8  
PREVALENCE IN DOGS 
 
 Giardia has been documented in animals worldwide.  A 2005 study in Japan reported 
that 40% of cats surveyed were infected with Giardia by a fecal ELISA methodology.  That 
study found a higher incidence in cats < 6 months of age and outdoor cats.  They found no 
relationship between the presence of the parasite and clinical signs.23  A survey of 250 cats in 
Mississippi and Alabama demonstrated that 13.6% of cats were shedding Giardia cysts when 
feces were evaluated using a centrifugation-flotation technique and a commercially available 
direct immunofluorescent antibody (IFA) kit.  In these cats, only 35% of the positive cats had 
diarrhea while 6.1% of cats shedding Giardia cysts were apparently healthy.  Of the Giardia 
infected cats in this study, 73.5% had a concurrent infection with Cryptosporidium spp.24   
Of the 130 dogs with diarrhea that presented to Colorado State University in 2003, 5.4% 
were positive for Giardia by flotation and an immunofluorescent assay.25  A survey done using 
the Snap® Giardia antigen test from IDEXX Laboratories, Inc. Westbrook Maine,a found an 
overall prevalence in dogs with gastrointestinal symptoms of 15.6% in the US.  Regionally the 
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prevalence ranged from 19.2% in the northeast to 12.9% in the southeast.26  Giardia has been 
found in many species of animals from beavers, river otters, coyotes, water buffalo and mollusks 
in all areas of the world.7, 27-30 
PREVALENCE IN HUMANS 
 
   Giardia spp. has been documented in humans worldwide and the prevalence depends on 
the geographic location.  Voluntary reporting to the CDC shows that annually between 20,075 to 
24,225 cases of giardiasis occurred in people within the United States between 1998 and 2003.31  
The largest numbers of cases were reported in children 1-9 years of age and adults between 30-
39 years of age.  There also appears to be a summer seasonal peak of cases.31, 32  In Australia, in 
2002, children were screened for the presence of Giardia.  Of the 1306 samples evaluated, 7.6% 
(99 samples) were found to be positive by microscopy.  Thirty-five percent of the positive 
children were positive more than once on subsequent testing. Twenty three isolates were 
successfully genotyped with 7 being assemblage A and 16 being assemblage B.  The children 
infected with assemblage A were 26 times more likely to have diarrhea, although both groups 
had asymptomatic children.  In that study no asymptomatic children became symptomatic.33   
These results conflict with what was found in 2001 in the Netherlands. A study enrolled 18 
patients which had signs of diarrhea and were positive for Giardia.  They were split into two 
groups, intermittent diarrhea vs. chronic persistent diarrhea. Their findings showed a strong 
correlation between assemblage A and intermittent diarrhea. Patients with persistent diarrhea 
were more often infected with assemblage B.34  The conflicting results of these studies illustrate 
assemblage and clinical signs may not be linked. 
ZOONOSIS 
 
Interestingly epidemiological evidence is sparse supporting the importance of zoonotic 
transmission of Giardia.7  In New Zealand, contact with pets was not identified as a risk factor 
for giardiasis in children or adults.7, 16, 43   Similarly, studies in the USA, Canada and UK have not 
found animal contact a risk factor for human giardiasis.7    
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Studies indicated the majority of human infections occur with assemblage A and B 
organisms. In the A assemblage, the subtype AII is more common in people while animals 
infected with assemblage A are more likely to harbor subtype AI.  However, infections with both 
subtypes have been documented in humans as well as many species of animals.7   
When the aboriginal people of Australia were surveyed it was found that they harbored 
the G. intestinalsis assemblage A and B while the indigenous dog population carried assemblage 
C and D.  It was noted that in this community people do not cohabitate with the dogs.44  The tea 
growing community of India has a large population of pet dogs which roam freely and enter the 
owner’s homes.  All of the human samples were of assemblage A or B; the dogs also harbored 
assemblage A and B.45  When humans and animals in the Netherlands were sampled, the Giardia 
spp. from people were found to be assemblage A and B, while the dogs were found to have 
assemblage D, the goats had assemblage E and the deer had assemblage A.46  Other studies 
conducted in central and northern Italy found mixed populations of assemblages in domestic 
animals. Dogs were found to harbor assemblages C, D, A and A& D, the single cat examined 
had assemblage F and calves had assemblages A, E and B. One of the isolates from a calf was 
identical to a human assemblage B isolate.6  A Maryland farm found 12% of the ewes and 4% of 
the lambs to be infected.  One ewe carried assemblage A, all the rest harbored Assemblage E.47  
Portuguese calves were found to have a prevalence rate of 25.4% while 4.5% of adults were 
shedding.  Assemblage E was the predominant type but B and AII were also found.48   Seven 
horses from the state of New York and 2 horses from Australia were identified as carrying 
assemblage AI, AII, and B.49  Recently in Egypt, 34.6% of 52 fecal samples from people 
evaluated were positive for G. intestinalisis.  Genotyping using the TPI loci was performed.  Of 
the 18 positives samples, 1 was assemblage A, 14 were assemblage B and 3 were assemblage 
E.50   
A study took Giardia cysts from asymptomatic children in Brazil and grew them in 
culture.  The Giardia cysts and trophozoites were orally administered to dogs.  All dogs started 
shedding cysts on day 5 or 6 post inoculation.  No dogs had clinical signs of illness.  This study 
shows dogs can be become infected when given Giardia from a human source. Unfortunately 
genotyping was not done in this study.16  These findings illustrate the need for continual 
surveillance to further understand the epidemiology of this parasite. 
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TESTING 
 
 In veterinary medicine centrifugation fecal flotation method has been traditionally used 
with zinc sulfate, Sheather’s sugar or sodium nitrate flotation solutions for the identification of 
Giardia cysts.  Due to the intermittent nature of cyst shedding it has been reported that multiple 
fecal samples maybe needed to achieve correct diagnosis.35  In addition due to the small size of 
the cysts, microscopes should be equipped with an ocular micrometer to allow measurement and 
considerable skill is needed for correct identification of the parasite.  This is often a stumbling 
block for the clinical practitioner and veterinary technician.   
Sheather’s sugar solution is an excellent solution for routine fecal flotations, but causes 
the Giardia cysts to appear crescent shape due to the disruption of the cyst’s internal structures.35  
Zinc sulfate solution, while producing less distortion and disruption of the cysts, fails to float 
heavier parasite eggs such as Taenia spp. and Physaloptera spp.35  Saline wet mounts from direct 
fecal smears is an insensitive way to recover many gastrointestinal parasites due to the small 
sample size evaluated  and data on reliability of direct smears for recovery and identification of 
Giardia  trophozoites and cysts is lacking.35  To recover trophozoites in a saline wet mount, feces 
must be fresh and nonrefrigerated.  Trophozoites may be observed more commonly in diarrheic 
feces.  Trophozoites die quickly, so immediate evaluation of the slide is needed.  Trophozoites 
have a characteristic “falling leaf” motion that aids in differentiating Giardia spp. from 
Tritrichomonas foetus and Pentatrichomonas hominus.36  
Immunofluorescent antibody (IFA) assays are available commercially.  A fluorescent 
conjugated monoclonal antibody to cyst wall antigen is used to coat the surface of the parasite.  
The cyst fluoresces when using a light source with wavelength of 490 – 500 to excite it. The 
fluorescing cysts can then be visualized using a fluorescent.37  While this is a highly specific test, 
to visualize the fluorescence one needs a fluorescent microscope equipped with the proper filter 
as select the wavelength of the fluorescent dye. These requirements make this procedure 
impractical and cost prohibitive for use in private practice.    
The polymerase chain reaction (PCR) has revolutionized the field of molecular 
diagnostics.  It allows scientists to amplify an organism’s DNA without the time consuming and 
often unsuccessful need to culture the parasite.  PCR techniques have been developed for several 
Giardia spp. gene loci, such as the SSU-rRNA, elongation factor1-alpha, Triosephosphate 
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isomerase, glutamate dehydrogenase, and ß-giardin.38  The technology is highly specific but 
sensitivity fluctuates.  A 2007 study showed that a FTA filter paper method for cyst capture to be 
the most effective.  It was capable of detecting as few as 168 cysts per ml. The SSU-rRNA gene 
loci using primers RH11/RH4 and GiarF/GiarR was the most sensitive loci to locate.38  While 
this technology has advanced scientific study greatly, it is not yet ready for mass screening of 
fecal samples from veterinary practices.  
 IDEXX Laboratoriesa has marketed a Giardia fecal antigen test for in-clinic use at 
veterinary practices.  The SNAP®   test from IDEXX is a lateral flow chromatographic assay 
designed to detect cyst wall protein. Encystation vesicles release cyst wall proteins when forming 
the cyst outer wall some escapes in to the feces and this is what the SNAP® test is detecting.39, 40  
According to manufacturer’s instructions this test can be performed on fresh feces, previously 
frozen feces or feces that have been refrigerated at 2°-8°C for  7 days.  The SNAP device, 
reagent and feces must be at room temperature prior to performing the test.  This test is easy to 
run and interrupt the results.  The gold standard for comparison is the IFA. In one study 
comparing the IFA assay and SNAP® Giardia fecal antigen test, the IFA assay detected 24% of 
the samples to be positive and 13% of the samples were positive by SNAP® test.41  Another study 
in cats compared zinc sulfate centrifuged fecal flotation, enzyme immunoassays and an IFA 
assay. It was found that the zinc centrifugation fecal flotation and IDEXX SNAP® test had very 
comparable results. The float was 85.3% sensitive and 99.7% specific and the IDEXX SNAP® 
test was 85.3% sensitive and 100.0% specific.42  A personal observation is that there is no 
correlation between the coloration of a positive test and a number of cysts being shed.   
 
TREATMENT AND CONTROL 
 
Medications such as nitroimidiazoles, benzimidazoles, furazolidine, nitazoxanide and 
quiniacrina have all been used successfully in people for the treatment of giardiasis. No 
medications are approved for the treatment of Giardia in animals in the United States. 
Fenbendazole is approved for the treatment of Giardia in dogs in Europe. Veterinary medicine 
has relied most heavily on metronidazole, fenbendazole and febantel. 
 12 
Metronidazole has been used successfully for years. Metronidazole at a dose of 25mg/kg 
every 12 hours for 7 days eliminates the organism in cats experimentally infected with Giardia 
from a human host.  This regimen was efficient in eliminating the organism.17   Metronidazole 
utilizes the anaerobic metabolic pathways present in the Giardia organsim. The drug is taken in 
to the parasite and activated by reduction of the nitro group. The reduced drug form will 
covalently bind to the parasites DNA. The result is DNA damage and inhibition of trophozoite 
respiration.51  Resistance to metronidazole has been induced in vitro.51  
Fenbendazole is in the benzimidazole class of parasiticides. This chemical exerts its toxic 
effect on the Giardia organism by binding to the β-tubulin cytoskeleton. The binding causes both 
inhibition of cytoskeleton polymerization and impaired glucose uptake. This ultimately causes an 
inhibition of energy metabolism.51  Dogs treated with 50mg/kg of fenbendazole orally for 3 days 
and given a bath after the last treatment, showed reduce shedding of cysts by 90%.52, 53  Cats 
infected with Giardia from a human host were treated with 50mg/kg/day of fenbendazole orally 
for 5 days.  Cysts shedding fell to non-detectable levels in 4 of the 8 cats. Three cats had reduced 
shedding and one cat had no shedding for one week then resume shedding cysts. These cats were 
coinfected with Cryptosporidium sp. and no baths were given after treatment.54  
A combination product of febantel, praziquantel, and pyrantel (Drontal® Plus) is marketed 
as a broad spectrum dewormer for dogs. Febantel is metabolized to fenbendazole and 
oxyfenbendazole.53  Drontal has been shown to be effective in dogs after 3 to 5 days of 
administration with the febantel dosed at 25-35mg/kg.53, 55  Efficacy of treatment can be 
increased by giving treated dogs a bath on the last day of treatment. 53 
Furazolidone undergoes reductive activation in the trophozoite. The antiprotozoal effects 
cause damage to cellular components including DNA. Resistance to furazolidone is caused by 
decreased entry of the drug into the parasite or with increased levels of thiol-cycling enzymes, 
which defend against toxic radicals.51  Furazolidone is currently not widely used for the treatment 
of giardiasis in veterinary medicine due to the unwanted side effects of vomiting and decrease in 
appetite.17 
Nitazoxanide is thought to inhibit the pyruvate:ferredoxin/flavodoxin oxidoreductase 
enzyme-dependent electron transfer reaction(PFOR system). Nitazoxanide is a noncompetitive 
inhibitor of the PFOR system in Giardia.  It has been proposed that nitazoxanide inhibits the first 
step in the PFOR reaction by interfering with the binding of pyruvate to the thiamine 
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pyrophosphate cofactor.56  This drug is not commonly used and little information about dosing 
for dogs and cats is available at this time.  
Two newer drugs may be effective for use in the treatment in animals. Tinidazole 
(Tindamax or Fasigyn) has recently been approved for treatment of giardiasis in people in the 
United States.57  It is a second generation nitroimidazole.  Its mechanism of action is not clearly 
understood, but thought to act via production of cytotoxic free radicals.58  A similar drug, 
ronidazole (Ridzol) has been used for treatment of Blackhead in turkeys caused by the protozoa 
Histomonas melagris and recently recently explored as a treatment for Tritrichomonas foetus in 
cats.59   
Eliminating re-exposure to infective cysts is important to decreasing reinfection.  A bath 
for the animal after the last dose of medication will remove infective cysts that are remaining on 
the animal’s coat.  Environmental cleanup is essential in controlling re-exposure.53   
 
VACCINE 
 
In 1999 a vaccine approved for dogs and cats became available from Fort Dodge Animal 
Health, Fort Dodge, IA. C  The vaccine consists of chemically inactivated trophozoites.  Initial 
studies in kittens showed the vaccine decreased number of cysts being shed, a decrease number 
of trophozoites in the small intestine of infected cats, decrease number of cats with trophozoites 
in the small intestine and decrease viability of the cysts.60   In another study the same author 
evaluated the vaccine in 13 dogs that were infected with Giardia and had not cleared of infection 
with medication.  All dogs had a decrease in their clinical signs and cessation of shedding of 
cysts after vaccination.61  Puppies that had been vaccinated showed a significant decrease in 
number cysts as compared to controls.62  Subsequent studies in different laboratories have shown 
the vaccine did not change the course of the infection in cats, did not significantly decrease cyst 
shedding in asymptomatic research dogs and did not prevent recurrence of cysts in the feces 
from research dogs.53, 63, 64  The 2006 AAHA canine vaccine guidelines place the Giardia 
vaccine in the not recommended category.65  
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Vaccines may be useful in the future.  Research has produced a novel DNA vaccine 
encoding for Giardia cyst wall protein 2 using a Salmonella typhimurium bactofection vehicle 
for use in mice.  The vaccine led to a mixed Th1/Th2 cellular immune response as well as IgA 
and IgG cyst wall protein 2 antibodies found in intestinal secretions of the vaccinated mice.  
After challenge with Giardia muris, vaccinated mice had a 60% reduction in cysts shedding 
compared to control mice.66 
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CONCLUSION 
  
Giardia is a common intestinal parasite infecting a variety of hosts worldwide.   This 
parasite was once thought to be an evolutionarily simplistic organism; now new research is just 
starting to unlock some of the secrets about the parasite that affects so many species.  New 
research techniques will help to differentiate the molecular differences between species and 
assemblages of Giardia. This may help to resolve the debate about the zoonotic/anthroponic 
potential of this parasite.  The prevalence of the Giardia is not likely to diminish.  The more we 
know the more it becomes obvious that we should not rely solely on pharmaceuticals as the 
answer for control of this parasite.  Novel methods for environmental control and treatment are 
needed.  Currently there is an abundance of information known about this parasite but we are a 
long way from knowing all there is to know about Giardia. 
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CHAPTER 2 -  Comparison of the Snap® Giardia Fecal Antigen Test 
and the Zinc Sulfate Double Centrifugation Fecal Flotation to 
Diagnose Giardia intestinalis Infections in Two Populations of 
Infected Dogs 
INTRODUCTION 
 
Giardia is a common intestinal protozoan parasite of pet dogs and cats.  This parasite has 
two morphological forms, trophozoites and cysts.  Trophozoites are the motile form found within 
the intestinal lumen.  Trophozoites measure approximately 8 μm wide by 15 μm long.  They can 
be identified by the presence of two anterior nuclei, axonemes present between the nuclei, the 
median bodies in the posterior third of the organism, and four pairs of flagella.10, 11,67   These 
structures give the trophozoites their unique face-like appearance.  Trophozoites start the 
encystation process when cues such as the presence of bile salts, fatty acids and a change to an 
alkaline pH, are detected in the small intestine.67  Cysts are the environmentally resistant form of 
the parasite. Most infections occur by ingestion of cysts which are immediately infective after 
being passed into the environment. They are approximately 7 μm wide by 12 μm long.  Cysts 
contain two incompletely separated trophozoites.  Internal structures that can be visualized are 
the axonemes, fragments of the ventral disks and nuclei.  The cysts protective outer wall allows 
the organism to survive outside the host.2  Cysts can survive long periods of time in cold wet 
areas but are susceptible to destruction in hot arid environments.20-22  Infection typically occurs 
through ingestion of cysts.  Once the cysts are ingested and pass through the stomach, 
excystation occurs allowing the trophozoite form to proliferate.10, 26, 67   The prepatent period of 
Giardia spp. has been found to be 5 – 16 days.16, 18, 19   
Veterinarians commonly attempt to diagnose giardiasis in clinic by direct smear saline 
wet mounts, fecal flotation or the Snap® Giardia antigen test by IDEXX laboratories b.  When 
observed using saline wet mounts, the motile trophozoites have a tumbling or falling leaf 
motion.36   Direct smears are considered a the least sensitive diagnostic technique due to the 
small amount of feces being evaluated and lack of concentration of the sample.35  Fecal flotation 
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is used for recovery and identification of cysts.  Zinc sulfate is commonly used as the flotation 
solution because it is effective in floating the cysts with minimal distortion to the internal 
structures.35  Cysts can also be stained with Lugol’s iodine for easier visualization.  Sugar 
flotation solutions used for routine fecal exams can cause distortion of the cysts making them 
more difficult to identify.  Technical skill is needed to correctly identify cysts as they can easily 
be confused with yeast or other small debri.35   As trophozoites are encysting, cysts wall proteins 
are made and packaged into encystation vesicles. These vesicles come to the surface of the 
organism and release the cyst wall proteins that are incorporated in the  protective outer covering 
of the cyst.68   The ELISA based technology of the Snap® Giardia antigen test uses antibodies 
specific to Giardia cyst wall proteins released into the feces during the encystation process.  The 
lateral flow technology allows a blue color to be visualized when antibody binds Giardia cyst 
wall antigen.39, 40  Other diagnostic methods such as immunofluorescent assays and PCR are 
available at diagnostic laboratories but are not suited to be used as an in-house diagnostic test at 
veterinary clinics. 
Due to intermittent cyst shedding it has been shown that flotation of three separate fecal 
samples from one individual will increase the accuracy of the diagnosis of giardiasis.35, 69  
However, in most veterinary practices it may be difficult to conduct fecal flotation or Snap® tests 
on three fecal samples. 
 Although there are several proven therapies for treatment of Giardia in dogs; no 
medications are labeled for the treatment of giardiasis in the dog in the United States.  The most 
common medications used for treatment include metronidazole, fenbendazole, and Drontal® Plus 
containing febantel.  Febantel is metabolized to fenbendazole and oxyfenbendazole.52, 53, 55  It is 
also well recognized that a bath on the last day treatment is extremely important to remove 
infective cysts from the hair coat of the animal.53  Environmental control measures including 
washing bedding, washing food and water bowls, and immediate clean up of feces with 
appropriate disposal may help reduce the risk of immediate reinfection.  
After a diagnosis, appropriate therapy, and environmental control, the next question for 
veterinarians is when to retest. While it has been suggested that the IDEXX Snap® fecal ELISA 
test will remain positive for up to two weeks after successful treatment, there is no published 
data to indicate whether this true.b 
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The goals of this study were to compare the IDEXX Snap® fecal ELISA test and a zinc 
sulfate double centrifugation fecal float in detecting Giardia infections in dogs.  Also, to 
determine if there is an increase in the diagnostic sensitivity when three fecal samples from one 
dog where analyzed daily or were combined into a composite sample for evaluation by both 
methods.  Finally, how long after treatment with Drontal® Plus and a bath will fecal samples 
remain positive with the IDEXX Snap® fecal ELISA test or zinc sulfate double centrifugation 
fecal flotation. 
 
METHODS AND MATERIALS  
 Assessment of feces  
Forty nine purpose-bred research beagles from a facility with a history of chronic Giardia 
infection (Group 1), and eighteen dogs of various breeds from a commercial kennel and twelve 
dogs from a  regional animal shelter (Group 2) had fecal samples collected on three consecutive 
days.  A zinc sulfate double centrifugation flotation was performed on each fecal sample.  The 
zinc sulfate centrifugation technique was conducted using approximately five grams of feces.  
Twenty mLs of tap water was added to each sample.  The samples were suspended in the water 
and strained into a 40mL centrifuge tube.  This suspension was centrifuged for 5 minutes at 
280xg.  The supernatant was discarded.  The sediment was resuspended with a zinc sulfate 
solution with a specific gravity of 1.18.  This solution was poured into a 12 mL centrifuge tube 
and filled to a slight positive meniscus.  An 18mm2 cover slip was placed on top of the tube. The 
samples were centrifuged in a swinging-head centrifuge for 5 minutes at 280x g, and then 
allowed to stand for 10 minutes.  A drop of Lugol’s iodine was placed on a slide and the cover 
slip was transferred to the slide.  The slide was examined at 100X magnification by personal in 
the K-State Veterinary Parasitology Diagnostic Laboratory trained in Giardia cyst identification.  
Each fecal sample was also evaluated using the Snap® Giardia antigen test.a    The tests 
were performed according to product insert directions. The test kits were stored at 2°C (35.6 °F) 
and were allowed to come to room temperature prior to use. The test kit swab, after being 
removed from the plastic sleeve, was coated with a thin layer of fecal material from each sample. 
The plastic sleeve was replaced and the reagent was mixed by breaking the valve stem and 
pressing the bulb three times.  The plastic sleeve was removed and five drops of the 
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sample/conjugate solution was placed in the sample well of the Snap® test devise.  When the 
sample solution first appeared in the activation circle of the Snap® test devise, it was depressed.  
After eight minutes the test result was read.  A blue colored will appear in the sample circle if the 
test is positive for detecting of Giardia cyst wall protein.39  
For Group 1, purpose bred research beagles, fecal samples that were positive by both 
methods were considered diagnostic for Giardia.  Any fecal sample that was not positive by both 
diagnostic test methodology (flotation or Snap® Giardia antigen test), was also evaluated using 
the MeriFluor® Cryptosporidium/Giardia immunofluorescent antibody assay (IFA).c  In 
preparation for the IFA assay a concentrating procedure was conducted to maximize cyst 
recovery.  Two grams of feces from each sample was suspended in 1.5X phosphate buffer saline 
with EDTA and strained through sterile gauze.  The liquid was layered on 7mLs of a sugar 
solution (specific gravity of 1.13) in a 15mL centrifuge tube. The tubes were centrifuged at 800 x 
g for 10 minutes in a fixed angle centrifuge.  After centrifuging, the interface was pipetted off 
into a new 15 mL centrifuge tube.  PBS-EDTA was added to bring the volume to 12mLs.  The 
sample was centrifuged at 1200 x g for 10 minutes. The supernatant was decanted and 
resuspended in 8 mLs PBS-EDTA.  The tube was then centrifuged for 10 minutes at 1200 x g.  
Again, the supernatant was decanted.  The pellet was resuspended with PBS-EDTA to a volume 
1 ml.  15 μL of sample was placed on one well of the Merifluor slide.70   Positive and negative 
controls were applied to separate wells.  The samples were allowed to air dry on to the slides for 
approximately 30 minutes.  The slides were stained according to product directions with a 
fluorescein isothiocyanate (FITC) labeled monoclonal antibodies to Giardia cyst wall antigen.   
The slides were incubated in a room temperature (21°C/ 69.8°F) chamber in the dark for 30 
minutes. After incubation, the slides were rinsed with a buffer wash supplied by the test kit and a 
drop of mounting medium was applied. A cover slip was placed and the slide was viewed at 
100X magnification with a fluorescent microscope with a filter system for FITC with the 
following parameters: Excitation wavelength consistent of- 490-500 nm, and a barrier filter - 
510-530 nm were used to identify the presence of fluorescent Giardia cysts.37  
To produce a composite sample approximately 2 grams of feces were collected from each 
of the three daily fecal samples and combined in a cup and thoroughly mixed with a wooden 
tongue depressor.  Using the composite sample, a Snap® Giardia antigen test and zinc sulfate 
double centrifugation flotation were performed as previously described.  Samples that were 
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positive by both methods were considered diagnostic for giardiasis.  Samples that were not 
positive by both methodologies had the IFA performed as described using 1 gram of the 
composite sample. Based on the performance of the Snap® Giardia antigen test and zinc sulfate 
double centrifugation in Group 1 purpose-bred research beagles it was decided that for Group 2 
dogs the IFA assay would be performed on every fecal sample. 
Twenty three beagles (Group1) were available for post treatment diagnostic evaluation. 
The dogs were treated with Drontal® Plus tabletsd (68.0 mg praziquantel, 68.0 mg pyrantel base 
as pyrantel pamoate and 340.2 mg febantel.) The beagles were administered the label dose of 
Drontal® Plus orally once daily for three consecutive days so they received 25 – 35mg/kg (11.36 
– 15.90 mg/lb) febantel daily.  On the last day of treatment a bath was performed using a 
detergent based non-insecticidal pet shampoo. Following bathing the dogs were returned to their 
cleaned runs. Eleven (11) of the research beagles were housed individually in indoor concrete 
runs and twelve (12) research beagles were housed individually in in/outdoor concrete runs. The 
runs were cleaned daily with water. Once to twice weekly the concrete runs were scrubbed with 
soap and water and sanitized with Coverage Plus NPD®e, a product consisting of four quaternary 
ammonium compounds. Fecal samples were collected from the treated dogs every other day 
starting one day post treatment for 21 days.  A total of eleven samples from each dog were 
collected.  A zinc sulfate double centrifugation flotation, Snap® Giardia antigen test and the 
MeriFluor® Cryptosporidium/Giardia immunofluorescent assay were performed on each sample. 
The three tests were conducted as described above. 
 
STATISTICAL ANALYSIS 
 
Detection methods for Giardia were initially analyzed separately for Group 1, purpose 
bred beagles, and Group 2, shelter and commercial kennels, dogs due to differences in the 
population of dogs.  Data for the two groups of dogs were analyzed as follows. In the first 
analysis, to compare the three methods, samples from the three individual days and the 
composite samples were all analyzed separately using Cochran’s Q ( at a significant level of 
0.05) because of within dog correlation.71 When Cochran’s Q was significant, pairwise 
comparisons were done between methods using McNemar’s test 71 with the significant level of 
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0.05.  Group 2 shelter and commercial kennels dogs, this analysis was conducted using all n=30 
dogs.  However, because the IFA analysis was not complete for all laboratory beagles, sub-
analysis were conducted to compare the testing methods.  McNemar’s test with a significance 
level of 0.05 was used to compare the fecal flotation and fecal ELISA methods on 37 of the 
group 1 dogs. McNemar’s test with a significance level of 0.05 was also used to compare 32 of 
the group 1 dogs that had all three methods of testing performed. 
An analysis pooling the two groups was a Pearson’s Chi-square test of homogeneity to 
test if the groups differed with respect to Giardia status as measured by either fecal flotation or 
fecal ELISA, separately for the three individual days and the composite sample. 
Finally, a pooled proportion of positive testing dogs were calculated for each group and 
detection method by defining “positive” as dogs that had tested positive on at least one the of 
three individual days by a specific method and “negative” as dogs that did not test positive on 
any of the three days by a specific method.  The calculated proportion with a 95% confidence 
interval is reported for each group and method.  
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RESULTS 
Comparison of diagnostics tests 
 
Group 1-  Thirty-seven of the 49 dogs in Group1 were found to be shedding Giardia 
cysts on at least one of three fecal samples by either the zinc sulfate double centrifugation fecal 
flotation, the Snap® Giardia antigen test, or IFA. (Table 2.1)  Thirty-six beagles had at least one 
fecal sample test positive with the IFA. One beagle was positive by fecal flotation and the Snap® 
Giardia antigen test (fecal ELISA test) on all three individual daily fecal samples and the 
composite sample so an IFA was not performed.  Of the beagles identified as shedding cysts on 
at least one of the 3 days, cysts were recovered in 22 (59.5% ), 20 (54.1%) and 19 (51.4 %) of 
the 37 fecal samples collected on days, 1, 2 & 3, respectively using the zinc sulfate double 
centrifugation fecal flotation technique.   Fecal ELISA tests were positive in 8 (21.6%), 18 
(48.6%) and 15 (40.5%) of the 37 fecal samples collected on days, 1, 2 & 3, respectively.  The 
composite samples had cysts recovered by fecal flotation in 23 of the 37 (62.2%) samples and 12 
of 37 (32.4%) were fecal ELISA positive. 
 
Table 2.1 Purpose bred beagles (Group 1) positive for Giardia by either fecal flotation or 
Fecal ELISA on daily fecal samples and a composite fecal sample  
Fecal Sample1 Fecal Flotation positive3 Fecal ELISA Positive4 
Day 1 22/37  (59.5%)a  8/37  (21.6%)b 
Day 2 20/37  (54.1%)a 18/37  (48.6%)a 
Day 3 19/37  (51.4%)a 15/37  (40.5%)a 
Composite sample2 23/37  (62.2%) 12/37  (32.4%) 
 
1 Fecal samples were collected daily for 3 days from each beagle  
2 A 2 gm sample from each of the 3 days was combined to make a composite sample  
3 Zinc sulfate double centrifugation fecal flotation stained with Lugol’s iodine 
4 IDEXX Snap® Giardia cyst antigen test kit 
Value within rows with unlike superscripts are significantly different (p>0.05) 
 
In Group 1, thirty-two of the 49 beagles had fecal flotation, fecal ELISA, and fecal IFA 
done on every fecal sample and cysts were seen on at least one of the 3 days.  Cysts were 
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recovered in 19 (59.4% ), 15 (46.9%) and  14 (43.8 %) of the 32 fecal samples collected on days, 
1-3 respectively, using the zinc sulfate double centrifugation fecal flotation technique.   Fecal 
ELISA tests were positive in 5 (15.6%), 13 (40.6%) and 11 (34.4%) of the 32 fecal samples 
collected on days, 1, 2 & 3, respectively.  Fecal IFA tests were positive in 23 (71.9%), 21 
(65.6%) and 26 (81.3%) of the 32 fecal samples collected on days 1-3 respectively.  Composite 
fecal samples were positive 18/32 (56.3%), 8/32 (25.0%), and 28/32(87.5%) of the time using 
fecal flotation, fecal ELISA and IFA, respectively. 
 
Table 2.2 Purpose-bred beagles (Group 1) positive for Giardia by fecal flotation, fecal 
ELISA or fecal immunofluorescent assay on daily fecal samples and a composite fecal 
sample 
Fecal Sample1 Fecal Flotation positive3 Fecal ELISA Positive4 Fecal IFA Positive5 
Day 1 19/32  (59.4%)b 5/32  (15.6%)a 23/32  (71.9%)b 
Day 2 15/32  (46.9%)ab 13/32  (40.6%)a 21/32  (65.6%)b 
Day 3 14/32  (43.8%)a 11/32  (34.4%)a 26/32  (81.3%)b 
Composite sample2 18/32  (56.3%)b 8/32  (25.0%)a 28/32  (87.5%)c 
1 Fecal samples were collected daily for 3 days from each beagle  
2 A 2 gm sample from each of the 3 days was combined to make a composite sample  
3 Zinc sulfate double centrifugation fecal flotation stained with Lugol’s iodine 
4 IDEXX Snap® Giardia cyst antigen test kit 
5 MeriFluor® Cryptosporidium/Giardia immunofluorescent assay 
Value within rows with unlike superscripts are significantly different (p>0.05) 
 
Ten beagles had cysts visualized by fecal flotation in all three samples and 6 beagles 
were fecal ELISA positive on all three samples. (Table 2.3)  Ten beagles had cysts visualized by 
flotation on two of the three samples and10 beagles were fecal ELISA positive on two of the 
three samples. Eleven beagles had cysts visualized by flotation results on only one of the three 
samples while 3 beagles were fecal ELISA positive on only one of the three samples. Six beagles 
did not have cysts seen on flotation any of the three days and 18 beagles were fecal ELISA 
negative all three days. Thirty one of the 37 beagles had at least one day they were shedding 
cysts that could be identified using the flotation method. Nineteen of the 37 dogs had at least one 
fecal ELISA that was positive on at least 1 of the three samples. 
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Table 2.3 Purpose-bred beagles (Group 1) positive for Giardia on 1, 2, or 3 consecutive 
daily fecal samples using either fecal flotation or fecal ELISA 
Samples1 Fecal Flotation2 Fecal ELISA3 
0 positive samples  6/37  (16.2%) 18/37  (48.6%) 
1 positive sample 11/37  (29.7%) 3/37  (8.1%) 
2 positive samples 10/37  (27.0%) 10/37  (27.0%) 
3 positive samples 10/37  (27.0%)   6/37  (16.2%) 
At least 1 of 3 three samples 
positive 
31/37  (83.8%) 19/37  (51.4%) 
 
1 Fecal samples were collected daily for 3 days from each beagle  
2 Zinc sulfate double centrifugation fecal flotation stained with Lugol’s iodine 
3 IDEXX Snap® Giardia cyst antigen test kit 
 
Group 2 - Three fecal samples were collected daily from 30 shelter/commercial kennel 
dogs.  All of the Group 2 dogs were found to be shedding cysts on at least one of the 3 fecal 
samples. Giardia cysts were identified in 24 (80.0%), of the 30 fecal samples collected on each 
of days, 1-3 using the zinc sulfate double centrifugation fecal flotation technique, but these were 
not necessarily always the same dogs (Table 2.4).   Fecal ELISA tests were positive on 23 
(76.7%), 25 (83.3%) and 22 (73.3%) of the 30 fecal samples collected on days 1-3 respectively.  
Cysts were observed by fecal IFA on 28 (93.3%), 27 (90.0%) and 29 (96.7%) of the 30 fecal 
samples collected on days, 1, 2 & 3, respectively.  Zinc sulfate double centrifugation fecal 
flotation of the composite sample found 26 (86.7%) samples to have cysts visualized.  Twenty 
five (83.3%) of these composite samples were fecal ELISA positive. All of the 30 fecal IFA 
composite samples had cysts visualized.   
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Table 2.4 Shelter and commercial kennel dogs (Group2) positive for Giardia by either fecal 
flotation, Fecal ELISA or fecal immunofluorescent assay on daily fecal samples and a 
composite fecal sample. 
Fecal Sample1 Fecal Flotation 
positive3 
Fecal ELISA 
Positive4 
IFA5 
Day 1 24/30  (80.0%)a 23/30  (76.7%)a 28/30  (93.3%)a 
Day 2 24/30  (80.0%)a 25/30  (83.3%)a 27/30  (90.0%)a 
Day 3 24/30  (80.0%)a 22/30  (73.3%)a 29/30  (96.7%)b 
Composite sample2 26/30  (86.7%)a 25/30  (83.3%)a  30/30  (100.0%)b 
 
1 Fecal samples were collected daily for 3 days from each beagle  
2 A 2 gm sample from each of the 3 days was combined to make a composite sample  
3 Zinc sulfate double centrifugation fecal flotation stained with Lugol’s iodine 
4 IDEXX Snap® Giardia cyst antigen test kit 
5 MeriFluor® Cryptosporidium/Giardia immunofluorescent assay 
Value within rows with unlike superscripts are significantly different (p>0.05) 
 
 All 3 daily fecal samples were positive by zinc sulfate double centrifugation fecal 
flotation in 19 (63.3%) dogs, by fecal ELISA in 16 (53.3%) dogs and by IFA in 25 (83.3%) dogs 
(Table 2.5).   Two of the three fecal samples were positive by fecal flotation, fecal ELISA and 
IFA in 6 (20.0%), 9 (30.0%), and 4 (13.3%) dogs, respectively.  One of the three fecal samples 
were positive by fecal flotation, fecal ELISA and IFA in 3 (10.0%), 4 (13.3%) and 1 (3.3%) dog, 
respectively.  Two (6.7%) of the commercial kennel/shelter dogs were never positive by fecal 
flotation on any of the 3 daily fecal samples and one (3.3%) was never positive by fecal ELISA.  
Every dog was positive at least once by IFA.   
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Table 2.5 Shelter and commercial kennel dogs (Group2) positive for Giardia on 1,2 or 3 
consecutive daily fecal samples using either fecal flotation or fecal ELISA. 
Samples1 Fecal Flotation2 Fecal ELISA3 IFA4 
0 positive samples 2/30  (6.7%)       1/30  (3.3%)        0/30  (0%) 
1 positive sample 3/30  (10.0%) 4/30  (13.3%) 1/30  (3.3%) 
2 positive samples 6/30  (20.0%) 9/30  (30.0%)   4/30  (13.3%) 
3 positive samples 19/30  (63.3%)      16/30  (53.3%)  25/30  (83.3%) 
At least 1 of 3 
positive samples 
28/30  (93.3%) 29/30  (96.7%) 30/30  (100%) 
 
1 Fecal samples were collected daily for 3 days from each beagle  
2 Zinc sulfate double centrifugation fecal flotation stained with Lugol’s iodine 
3 IDEXX Snap® Giardia cyst antigen test kit 
4 MeriFluor® Cryptosporidium/Giardia immunofluorescent assay. 
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Post treatment results 
 
Twenty three of the beagles from Group 1 were available for the treatment phase of the 
study.  Interestingly within one day after the three day treatment protocol with Drontal® plus and 
a bath, all 23 beagles were negative by zinc sulfate double centrifugation fecal flotation, fecal 
ELISA and IFA.  Nineteen (82.6%) of the beagles did not re-shed cysts during the 21 day post-
treatment evaluation period.  Four beagles had cysts identified by either fecal flotation or IFA 
between days 17 and 21 post-treatment. Two also had positive fecal ELISA tests. (Figure 2.1) 
 
Figure 2.1  23 Beagles from Group 1 treated with the label dose of Drontal Plus for 3 days 
with a bath on the last day. Post treatment fecal samples evaluted by fecal flotation, fecal 
ELISA and IFA performed every other day for eleven samples or 21 days.  
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DISCUSSION 
  
Giardia is a common intestinal parasite encountered by veterinary practitioners.  It is well 
known that cysts are intermittently shed making accurate diagnosis challenging. Ideally three 
fecal samples should be collected on separate days and analyzed before a negative diagnosis is 
made.35  Historically, fecal flotation using 1.18 sp gr zinc sulfate as the flotation solution has 
been used to identify cysts.  Conducting the proper centrifugation technique along with 
appropriate training of personnel to properly identify the cysts is necessary.  Debris and yeast 
often resemble cysts and the small cysts are easily overlooked.  IDEXX laboratories have 
developed a table top ELISA based test that detects Giardia cyst wall antigen that is released by 
encysting trophozoites.39 
When evaluating the day 1 fecal samples from the purpose bred beagles (Group 1), 22 
had cysts recovered by zinc sulfate double centrifugation fecal flotation but only 8 were fecal 
ELISA positive. This disparity was significant.  The day 2  and day 3  fecal samples from the  
purpose bred research beagles (Group 1)  and all three samples from kennel/humane society dogs 
(Group 2) had no significant differences in the number of positive samples identified between the 
zinc sulfate double centrifugation flotation and the fecal ELISA  test methods.  
There was no difference in the number of positive samples identified between each 
individual sampling day and the 3-day composite sample from the purpose bred beagles and 
kennel/humane society dogs using the zinc sulfate double centrifugation flotation method. There 
was a difference with the second sample from the purpose bred beagles which had 18 fecal 
ELISA positive while the composite fecal sample found only 12 fecal ELISA positive.  There 
was no difference between fecal ELISA conducted on the 3-day composite fecal sample and 
fecal samples collected on days 1 and 3 from purpose bred beagles or all 3 daily fecal samples 
from kennel/humane society dogs. When making the 3-day composite fecal sample many 
variables are encountered. The intermittent shedding of cysts may have a dilution effect on the 3-
day composite fecal sample and cysts and cyst wall protein may start to degrade over time 
making it more difficult to obtain a positive diagnosis. The data indicates there is no advantage 
to performing diagnostic testing on a 3-day fecal composite sample over an individual sample.  
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Due to the intermittent shedding of cysts it has been previously shown that evaluating 
three fecal samples by flotation methods increase the sensitivity of finding a positive result up to 
94%.35, 72  In the Group 1 purpose bred research beagles, 31/37 (83.8%) dogs had at least one 
positive fecal out of the 3 fecal samples collected using the zinc sulfate double centrifuge fecal 
flotation. In contrast, the individual days results were 22 (59.5%), 20 (54.1%) and 19 (51.4%) 
out of 37 being positive on days 1, 2, and 3. This was also true for the fecal ELISA results. There 
were 19/37 (51.4%) dogs that had at least one positive sample out of three collected.  This 
contrasted from the individual days results of 8 (21.6%), 18 (48.6%) and 15 (40.5%) of 37 were 
positive on days 1, 2, and 3. 
 In the Group 2 shelter and commercial kennel dogs, 28/30 (93.3%) dogs had at least one 
sample out of three collected that were positive by double centrifuge fecal flotation. This 
contrasted from the individual days results of 24/30 (80.0%) were positive on each of days 1, 2, 
and 3.  Using the ELISA test there were 29/30 (96.7%) dogs fecal ELISA positive at least once 
out of the three samples collected.   This contrasts from the individual days results of 23 (76.7%), 
25 (83.3%) and 22 (73.3%) out of 30 being positive on days 1, 2, and 3.  
 Both groups of dogs had cysts detected intermittently. Both groups of dogs had individual 
animals with intermittently positive fecal ELISA tests. There was a striking difference in the 
number of times cysts were seen or ELISA’s were positive by either method between the two 
populations of dogs. Group 2 dogs had cysts seen and fecal ELISA’s positive more frequently 
than Group 1 purpose bred research beagles.  Group 1 dogs individual fecal samples has cysts 
seen using the fecal flotation method 22/37 (59.5%), 20/37 (54.1%) and 19/37 (51.4%) for each 
day’s sample. The fecal ELISA tests were positive 8/37 (21.6%), 18/37 (48.6%) and 15/37 
(40.5%) for each day’s sample. Group 2 shelter and commercial kennel dogs individual fecal 
samples had cysts seen using the fecal flotation method 24/30 (80%) for each day’s samples.  
The fecal ELISA test was positive 23/30 (76.7%), 25/30 (83.3%), and 22/30 (73.3%) for each 
day’s sample.  
The Group 2 shelter and commercial kennel dogs live in a more stressful and changing 
environment, with variable nutrition, possible parasitism with more than one parasite, and 
possibly other concurrent diseases.  The group 1 purpose bred beagles live in a controlled 
environment with good nutrition and no other parasites or concurrent diseases. The purpose bred 
research beagles have limited genetic diversity and may be living with a strain of Giardia which 
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may have been endemic in the research beagles’ environment.  In this laboratories experience 
purpose bred research beagles from suppliers are commonly infected with Giardia but rarely 
have diarrhea associated with these infections. It is speculated that these environmental and 
disease variables play a role in the diagnostic disparity between the purpose bred research 
beagles and the kennel/humane society dogs.  Based on these data the purpose bred beagle that is 
chronically infected with Giardia may not be a good model to use when evaluating Giardia 
diagnostic tests. 
The IFA methodology reliably found more cysts than either the double centrifugation 
flotation or the fecal ELISA in both group1 and group 2 dogs. The intermittent shedding of cysts 
makes it impossible for any one test methodology to find all the infected individuals from every 
sample; but IFA method found more dogs positive on any one day’s samples than either of the 
other two methods.  
Twenty-three beagles were used for post treatment diagnostic evaluation.  All the beagles 
were administered the labeled daily dose of Drontal® Plus for 3 days and were bathed on the last 
day of treatment.  Surprisingly all 23 treated dogs were negative one day post treatment by the 
double centrifuge fecal flotation, the fecal ELISA test and IFA methods.  Even given the 
inconsistent results observed with the diagnostic tests during the diagnostic phase of this study 
finding all 23 dogs negative within 24 hours of the last day of treatment was remarkable. These 
dogs remained negative for at least 17 days which is past the prepatent period of Giardia.  We 
were unable to discern whether the recovery of cysts in 4 purpose bred beagles between days 17 
and 21 post-treatment was caused by a treatment induced temporary suppression of cyst/antigen 
shedding or reinfection.  In our study where the dogs were followed for 21 days post-treatment, 
the treatment and bathing protocol was 82.6% effective. Knowing whether a dog is still shedding 
cysts and/or is fecal ELISA test positive after therapy before the end of the prepatent period may 
help a practitioner make treatment decisions. A positive result should have practitioners 
reevaluate client compliance, and treatment dosing. Resistance to medication can occur but is 
less likely than the previous two possibilities for failure to eliminate cysts. A positive result after 
the prepatent period could be caused by failure of the client to comply with treatment 
recommendations, inappropriate dosing of medication, resistance to medication, temporary 
suppression of shedding of cysts or reinfection. The recommendation to bath the dog on the last 
day of treatment and environmental control measures are critical to prevent reinfection.53 
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Eliminating cysts from the environment can be difficult but immediately picking up feces, 
washing of all the dogs’ bedding, and washing of food and water bowls with hot soapy water is 
the first step. Owners should consider avoiding places where cyst exposure is likely occur ( i.e. 
dog parks and camping) and find alternative places for exercise. Given that Giardia is a common 
parasite, reinfection is likely very common.  
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FOOTNOTES  
 
a) IDEXX Laboratories, Inc. One IDEXX Drive, Westbrook, Maine 04092 
b) Leif Lorentzen IDEXX Laboratories, Inc. One IDEXX Drive, Westbrook, Maine 04092 
personal communication 
c) MeriFluor® Cryptosporidium/Giardia Test, 3471 River Hills Drive, Cincinnati, OH 45244 
d) Drontal® Plus Bayer HealthCare, LLC. Animal Health Division, P.O. Box 390 
Shawnee Mission, KS 66201 
e) Coverage Plus NPD®, STERIS Corporation, 5960 Heisley Road, Mentor, Ohio 44060-1834 
USA  
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Appendix A - Project Photographs 
Figure A.1. The materials needed to perform a centrifuged fecal flotation; swinging head 
centrifuge, zinc sulfate solution (specific gravity 1.18), glass microscope slide, 12 ml 
centrifuge tube with fecal sample for flotation and 18mm2 glass coverslip. 
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Figure A.2 A centrifuged fecal sample is on the microscope slide with a coverslip and a 
drop of Lugol’s iodine. 
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Figure A.3. Giardia cysts visualized after floated in zinc sulfate solution stained with 
Lugol’s iodine magnified 400X. 
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Figure A.4. A SNAP® Giardia antigen test kit manufactured by IDEXX and a fecal sample. 
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Figure A.5. A positive and negative SNAP® Giardia antigen test is seen below. 
 
 
 
                                                  POSITIVE                               NEGATIVE 
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Figure A.6 Materials needed to perform the MeriFluor® Cryptosporidium/Giardia direct                
immunofluorescent assay; a fixed head centrifuged, PBS-EDTA solution, 15 ml conical 
centrifuge tube, and MeriFluor® Cryptosporidium/Giardia direct immunofluorescent assay 
microscope slide (rest of test kit not shown). 
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Figure A.7 Giardia cysts identified by the MeriFluor® Cryptosporidium/Giardia direct 
immunofluorescent test. 
 
 
Arrows are pointed to Giardia cysts which can be visualized due to fluorescent antibody 
coating the surface of the parasite. 
